Paul Chaplin, Bavarian Nordic CEO

US con­sid­ers use of ex­pired mon­key­pox vac­cines amid ris­ing de­mand for dos­es

As the US looks to stretch its stock­pile of Bavar­i­an Nordic’s mon­key­pox vac­cine, reg­u­la­tors are work­ing with the com­pa­ny to as­sess whether some ex­pired dos­es can still be used.

Bavar­i­an Nordic CEO Paul Chap­lin told Reuters on Wednes­day that about half a mil­lion ex­pired dos­es in the US’ na­tion­al stock­pile may still be vi­able, though it would be up to reg­u­la­tors to make the fi­nal call.

An FDA spokesper­son con­firmed to End­points News that it is “ac­tive­ly work­ing with Bavar­i­an Nordic and AS­PR/BAR­DA to ob­tain the nec­es­sary in­for­ma­tion to po­ten­tial­ly re­qual­i­fy a sub­set of ex­pired dos­es that meet cer­tain qual­i­ty spec­i­fi­ca­tions.” The New York Times re­cent­ly re­port­ed that about 20 mil­lion dos­es of the vac­cine have ex­pired in the US na­tion­al stock­pile.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.